Fibrinolytic and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and hemostasis

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 53-59

  Ridker, Paul M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ARTERY OCCLUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE MARKER; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0030809456     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657500     Document Type: Conference Paper

References (86)

1. Ridker PM. Association of hemostatic and thrombotic factors with cardiovascular risk. In Schafer A (ed). Molecular Mechanisms of Hypercoagulable States. RG Landes, New York; 1997.
2. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-8.
3. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343:940-3.
4. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-41.
5. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12:157-61.
6. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease: A seven year follow-up. Circulation 1993; 88:2030-4.
7. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 1993, 13:1412-7.
8. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
9. Meade TW, Ruddock V, Stirling Y, Charkrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-9.
10. Juhan-Vague I, Pyke SDM, Alessis MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
11. Folsom AR, Qamhieh HT, Wing RR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostasis factors in moderately overweight adults. Arterioscler Thromb 1993; 13:162-9.
12. Vague P, Juhan-Vague I, Aillaud MR, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35:250-3.
13. Ridker PM, Vaughan DE, Stampfer MJ, Sacks FM, Hennekens CH. A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100. Arteriosclerosis and Thrombosis 1993; 13: 1-6.
14. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promotor of the plasminogen activator inhibitor (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-45.
15. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphies SE, Evans A, Luc G, Cambou JP, Arveller D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemos 1995; 74:837-41.
16. Falk G, Almqvist A, Nordenhem A, Svensson H, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promotor region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995; 9:170-4.
17. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Nati Acad Sci USA 1995; 92:1851-5.
18. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promotor of the plasminogen activator inhibitor (PAI-1) gene in a large cohort of US men. Circulation, in press.
19. Tishkoff SA, Ruano G, Kidd JR, Kidd KK. Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Hum Genet 1996; 97:759-64.
20. van der Bom JG, de Knijff P, Bots ML, Haverkate F, Hofman A, Kluft C, Grobbee DE. Polymorphism of the blood clot lysis enzyme tissue type plasminogen activator is associated with myocardial infarction. Circulation 1995; 92 (Suppl 2):I-30.
21. Iacoviello L, Di Casstelnuovo A, de Knijff P, D'Orazio A, Amore C, Kluft C, Donati MB. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI). Fibrinolysis 1996; 10 (Suppl 2), 13-16.
22. Baker MT, Vaughan DE, Hennekens CH, Stampfer MJ, Ridker PM. Polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risk of future myocardial infarction. Circulation 1996; 94:1-460.
23. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70:584-7.
24. Meilahn EN, Kuller LH, Mathews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiology 1992; 2:445-55.
25. Fujii S, Sobel BE. Direct effects of gembibrozil on the fibrinolytic system. Diminution of synthesis of plasmiogen activator type 1. Circulation 1992; 85:1888-93.
26. Ridker PM, Vaughan DE, Stampfer MJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue plasminogen activator. JAMA 1994; 272:929-33.
27. Lee AJ, Flanagan A, Rumley A, Fowkes FGR, Lowe GDO. Relationship between alcohol intake and tissue plasminogen activator antigen and other haemostatic factors in the general population. Fibrinolysis 1995; 8:49-54.
28. Ridker PM, Vaughan DE. Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors. J Thromb Thrombolysis 1995; 1:251-7.
29. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin angiotensin system and fibrinolytic function. Circulation 1993; 87:1969-73.
30. Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:669-77.
31. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173-8.
32. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Card 1994; 24:67-73.
33. Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA, on behalf of the HEART study investigators. Effects of remipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation, in press.
34. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L. Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-5.
35. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533-7.
36. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258:1183-6.
37. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118:956-63.
38. Heinrich J, Balleisen L, Schulte H, Assman G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54-9.
39. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovascular Risk 1995; 2:197-205.
40. Nabulsi AA, Folsom AR, White A, et al. for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328:1069-75.
41. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3):199-208.
42. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113:1006-10.
43. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; 2:986-8.
44. Goldbout U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum HDL cholesterol and reducing triglycerides after myocardial infarction in patients with clinically manifest atherosclerotic heart disease (The Bezafibrate Infarction Prevention Study). Am J Cardiol 1993; 71:909-15.
45. Francis CW, Connaghan DG, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75(6):1170-7.
46. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90:2236-40.
47. Fowkes FGR, Lowe GDO, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342:84-6.
48. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: The ARIC Study. Circulation 1995; 91:284-90.
49. Entman ML, Ballantyne CM. Inflammation in acute coronary syndromes [Editorial]. Circulation 1993; 88:800-3.
50. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-9.
51. Libby P, Clinton SK. The role of macrophages in atherogenesis. Curr Opin Lipidol 1993; 4:355-63.
52. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90:775-8.
53. Frenette PS, Wagner DD. Adhesion molecules - Part II. Blood vessels and blood cells. N Engl J Med 1996; 335:43-5.
54. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary disease. Am J Cardiol 1990; 65: 168-72.
55. Pietila K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related artery after thrombolytic therapy. Eur Heart J 1993; 14:915-9.
56. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417-24.
57. Kuller LH, Tracy RP, Shaten J, Meilahn EN for the MRFIT Research Group. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidem 1996; 144:537-47.
58. Ridker PM, Cushman M, Stampfer M, Tracy R, Hennekens CH. Inflammation, aspirin, and risks of first myocardial infarction, stroke, and venous thrombosis in apparently healthy men. Submitted.
59. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serium C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic therapy. Eur Heart J 1996; 17:1345-9.
60. Casl MT, Surina B, Glojnaric-Spasic I, Pape E, Jagarinec N, Kranjcevic S. Serum amyloid A protein in patients with acute myocardial infarction. Ann Clin Biochem 1995; 32:196-200.
61. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis and Rheumatism 1992; 35:982-4.
62. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ, 1996; 312:1061-5.
63. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman M-R, Manninen V, Manttari M, Frick MH, Huttunen JK. Chronic chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116:273-8.
64. Thom DH, Grayston JT, Siscovick DS, Wang S-P, Weiss NS, Daling JR. Association of prior infection with chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268:68-72.
65. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineux N, Levy J, Blakeston C, Seymour CA, Camm AJ, et al. Association of Helicobacter pylori and chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995; 311:711-4.
66. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71:437-9.
67. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA 1990; 263:2204-7.
68. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335:624-30.
69. Ruddock V, Meade TW. factor VII activity and ischaemic heart disease: fatal and non-ftal events. Q J Med 1994; 87:403-6.
70. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66:351-5.
71. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, van de Loo. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70:550-3.
72. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohen PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84:613-7.
73. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338:1409-11.
74. Trip MD, Manger Cats V, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322:1549-54.
75. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
76. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. A prospective study of the platelet glycoprotein IIIa PLA1/A2 polymorphism and risks of myocardial infarction, stroke, and venous thrombosis. Lancet, in press.
77. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-57.
78. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704-9.
79. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
80. Rosengren A, Wilhelmsen L, Kriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population of middle aged men. Br Med J 1990; 301:1248-51.
81. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271:999-1003.
82. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Inv 1994; 24:444-53.
83. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270:2195-9.
84. Alfthan O, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9-19.
85. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-22.
86. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg, PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-7.